Please login to the form below

Not currently logged in
Email:
Password:

Lilly promotes Melissa Barnes to chief ethics and compliance officer

Will replace Anne Nobles who retires at the end of 2012

Melissa Barnes, LillyLilly has announced Melissa Barnes to take over as chief ethics and compliance officer once Anne Nobles retires at the end of the year.

Barnes will be promoted from her current role as VP and deputy general counsel, and will oversee the US pharma company's litigation, compliance and legal efforts.

She will report directly to company chair, president and CEO Dr John Lechleiter and will also serve on Lilly's executive committee.

Her predecessor Nobles had been with Lilly since 1990, becoming chief compliance officer in 2007.

During Nobles' time in the role, Lilly was found guilty of illegally marketing and promoting several of its drugs, including Zyprexa, resulting in a $1.4bn – at the time, the largest fine ever imposed on a US company.

As part of this settlement, Nobles agreed to lead Lilly's efforts to ensure great ethics and compliance behaviour, including the creation of four new positions in senior management.

Commenting on Nobles' departure, Lechleiter said: “Anne has provided critical leadership at a very important time for our company.

"Her contributions have been instrumental in building a comprehensive company-wide ethics and compliance programme. She has worked closely with Lilly business leaders to ensure that compliance is effectively integrated into our business plans and our day-to-day activities."

31st October 2012

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics